Combined therapy for obesity

Combined use of two and more drugs promoting weight loss may create potential health risks. Despite the fact that a combined drug therapy may provide rapid weight loss, the vast majority of physicians prescribe monotherapy of obesity to obese patients.

Over the past few years, two new combined slimming drugs went on sale – Qsymia (Phentermine and Topiramate) and Contrave (Bupropion and Naltrexone). Clinical studies have shown the efficiency and safety of Qsymia and Contrave combined drugs.

However, do not forget that almost all combined slimming drugs were withdrawn from the market many years after the approval. Therefore, before receiving the first results of long-term post-marketing studies, doctors will prescribe Contrave and Qsymia diet pills with caution.

Potential risks of combined obesity therapy

Phentermine and Fenfluramine

Female-RunnerOnes of the first drugs that began to be used as a combined therapy for obesity were Phentermine and Fenfluramine. In the USA, combination of these two drugs is more known under the name Fen-Phen. Just as Phentermine, Fenfluramine provides anorexigenic effect. Therefore, each of these drugs is effective in obesity monotherapy.

Combined use of Phentermine and Fenfluramine allows to increase anorexigenic effect and to reduce the risk of side effects. However, after it was proved that Fenfluramine drug could cause valvular heart disease, its sale was banned and it was withdrawn from the U.S. market.

Till 1997, Fenfluramine was sold in the USA under the trade name Pondimin. Phentermine drug is still sold in the USA by prescription only. You can buy Phentermine drug in the USA under various proprietary names, including nonproprietary name Phentermine Hydrochloride and original names Adipex and Suprenza.

Sibutramine and Orlistat

Unlike to Phentermine and Fenfluramine drugs (that have the same pharmacological activity), Orlistat and Sibutramine slimming drugs have different mechanism of action.

• Sibutramine increases saturation, suppresses appetite and may enhance thermogenesis.
• Orlistat does not participate in appetite regulation, but prevents the absorption of food fats in the gastrointestinal tract.

The combined use of Orlistat and Sibutramine has been tested in several clinical trials. The results of the studies have demonstrated that the combination of these drugs really helps to increase the speed of weight loss.

However, large-scale studies of combined obesity therapy with Orlistat and Sibutramine have not been conducted. Therefore, the safety of using Sibutramine pills in the combination with Orlistat pills has not been confirmed.

In addition, in 2010 Sibutramine was withdrawn from pharmaceutical markets of developed countries. So today, it is almost impossible to buy Sibutramine drug in the USA, Australia and Europe.

More than 10 years, Sibutramine drug was sold in the USA under the trade name Meridia. Orlistat drug was approved as an obesity treatment more than 15 years ago and buyers of slimming products better know it under the trade names Alli and Xenical.

If you want to use a few drugs at once to fight obesity or one drug containing several active ingredients, consult a pharmacist before a combined obesity therapy. If you decide to buy a combined slimming drug online, ask all your questions by phone or email before making the order.

Leave a Comment